ClinicalTrials.gov
ClinicalTrials.gov Menu

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00295919
Recruitment Status : Completed
First Posted : February 24, 2006
Last Update Posted : February 15, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Nant Operations Center, Children's Hospital Los Angeles

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2014
  Actual Study Completion Date : May 2015
Publications of Results:
Marachelian A, Kang MH, Hwang K, et al.: Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial. [Abstract] J Clin Oncol 27 (Suppl 15): A-10009, 2009.